PDF(Pubmed)
Abstract：
Primary clear cell adenocarcinoma of the vagina represents a rare form of cancer historically correlated with in-utero diethylstibestrol (DES) exposure. Mainstay treatment modalities include surgery, radiation, and chemotherapy. There has been a growing interest in immunotherapy in the field of oncology. KEYNOTE 826 demonstrated that patients with persistent, recurrent, or metastatic cervical cancer including patients who had adenocarcinoma showed improved progression and overall survival by the addition Pembrolizumab to chemotherapy plus or minus bevacizumab. To date, there are no documented cases using pembrolizumab as adjuvant treatment for active or recurrent vaginal clear cell adenocarcinoma. We present a case of a young patient with recurrent vaginal clear cell carcinoma who showed a complete and durable response to Pembrolizumab.
摘要：
阴道原发性透明细胞腺癌是一种罕见的癌症，历史上与子宫内己烯雌酚（DES）暴露有关。主要的治疗方式包括手术，辐射,和化疗。在肿瘤学领域对免疫疗法的兴趣日益增加。KEYNOTE826证明了患者的持续性，经常性,或转移性宫颈癌,包括腺癌患者,通过在化疗中添加Pembrolizumab加贝伐单抗或减贝伐单抗,显示出改善的进展和总生存期.迄今为止,对于活动性或复发性阴道透明细胞腺癌,没有使用派姆单抗辅助治疗的文献报道.我们介绍了一例复发性阴道透明细胞癌的年轻患者，该患者对Pembrolizumab表现出完全和持久的反应。
